Aclarion, Inc. (NASDAQ:ACON – Get Free Report) saw a large increase in short interest in February. As of February 15th, there was short interest totalling 247,100 shares, an increase of 1,730.4% from the January 31st total of 13,500 shares. Based on an average daily volume of 378,900 shares, the short-interest ratio is currently 0.7 days.
Analyst Upgrades and Downgrades
Several brokerages have commented on ACON. Ascendiant Capital Markets decreased their target price on shares of Aclarion from $502.50 to $435.50 and set a “buy” rating for the company in a report on Wednesday, November 27th. Maxim Group reiterated a “hold” rating on shares of Aclarion in a report on Friday, December 13th.
Get Our Latest Research Report on ACON
Aclarion Trading Down 20.3 %
Aclarion Company Profile
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
Read More
- Five stocks we like better than Aclarion
- How to Read Stock Charts for Beginners
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- How to Invest in Small Cap Stocks
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- ETF Screener: Uses and Step-by-Step Guide
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
